MedTrace Logo

Open-Label Study of ARD-0403 in Testosterone Deficient Men

NCT00562731 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2008-04-01

No results posted yet for this study

Summary

Male hypogonadism, a disorder associated with testosterone deficiency, is frequently seen in clinical practice and has significant effects on patient well-being. The purpose of this study is to investigate the efficacy and safety of ARD-0403 as a testosterone replacement therapy in testosterone deficient men.

Conditions

  • Hypogonadism

Interventions

DRUG

ARD-0403

Daily transdermal ARD-0403

Sponsors & Collaborators

  • Ardana Bioscience Ltd

    lead INDUSTRY

Principal Investigators

  • R Swerdloff · University of California, Los Angeles

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00562731 on ClinicalTrials.gov